Work

Why it is timely to bring a new hormonal male contraceptive to the public – A 35‐year perspective of the authors

Year: 2024

Type: review

Abstract: This perspective provides an overview of issues needed to bring a testosterone-progestogen combined transdermal male hormonal contraceptive to the market. Large-scale phase 2b trials are near completion and a pivotal trial to confirm efficacy and safety has been designed. We believe we are close to accomplishing the steps necessary to bring the first male-directed effective, safe, and reversible pharmaceutical contraceptive approach to the public. If successful, we believe it will provide a new option for couples to consider in their family planning.

Source: Andrology

DOI: 10.1111/andr.13724

Authors: Ronald S. Swerdloff, William J. Bremner

Institutions: University of California, Los Angeles, The Lundquist Institute, Harbor–UCLA Medical Center, University of Washington

Language: English

Topic: Reproductive Health and Contraception

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,090